09:36:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 Ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2019-11-19 08:00:14
Oslo, Norway, 19 November 2019

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 19th November 2019 resolved to grant Dr Gabriele Elbl, Vice
President Global Regulatory Affairs, 30,000 Performance Share Units ("PSUs") in
connection with her appointment and under the Company's equity incentive plan
that was approved at the Company's annual general meeting held on 25 April 2019
(the "AGM"). For further information about Dr Elbl please see the Company's
stock exchange announcement on 1 October 2019. Following the allocation, Dr Elbl
holds 30,000 PSUs, 0 options and 0 shares in Nordic Nanovector.

The Board of Directors of Nordic Nanovector has further resolved to grant 5,000
PSUs to a new employee under the Company's equity incentive plan that was
approved at the AGM.

In accordance with the resolution at the AGM the PSUs are secured by a
corresponding number of free-standing warrants. The sole purpose of the free
-standing warrants is to ensure delivery of shares in the Company upon exercise
of the PSUs. The free-standing warrants do not give the PSU-holder a right to
subscribe for any additional shares in the Company.

The terms and conditions of the PSUs, which are part of the Company's long-term
incentive plan for employees, are described on pages 24-25 in the Company's
annual report for 2018.



For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com



About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin[®], a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's
lymphoma (NHL). NHL is an indication with substantial unmet medical need,

representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin[®] in core markets.

Further information can be found at www.nordicnanovector.com.



This information is subject to a duty of disclosure pursuant to the Securities
Trading Act, Sections 4-2 and 5-12 / Oslo Stock Exchange's Continuing
Obligations, Section 3.2.